🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,413 results for “ACE” Clear

  1. LX3305 low dose

    LEXICON PHARMACEUTICALS, INC.

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  2. LX4211 Low Dose

    LEXICON PHARMACEUTICALS, INC.

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  3. LX6171 High Dose

    LEXICON PHARMACEUTICALS, INC.

    Age-Related Memory Disorders

    phase 2 small molecule completed

    1 trial

  4. LX7101 (0.125%)

    LEXICON PHARMACEUTICALS, INC.

    Primary Open-angle Glaucoma

    phase 2 small molecule completed

    1 trial

  5. LX9211

    LEXICON PHARMACEUTICALS, INC.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule completed

    1 trial

  6. LY3871801

    RIGEL PHARMACEUTICALS INC

    Rheumatoid Arthritis

    phase 2 small molecule completed

    1 trial

  7. La composición cualitativa y cuantitativa de cada sobre de placebo es la siguiente: Bicarbonato sódico 563,75 mg Diluyente/generador de efervescencia Ph Eur Ácido cítrico 410,0 mg Diluyente/generador de efervescencia Ph Eur Maltodextrina 651,25 mg Diluyente Ph Eur Sílice coloidal anhidra 10,0 mg Fluidificante/desecante interno Ph Eur Manitol 769,0 mg Diluyente Ph Eur Sacarina sódica 24,0 mg Edulcorante Ph Eur Aroma de naranja 72,0 mg Saborizante Espec.. interna Masa nominal 2.500 mg El polvo efervescente se

    The George Institute

    Amyotrophic Lateral Sclerosis (ALS)

    phase 2 small molecule active

    1 trial

  8. Ladarixin, Placebo to match Ladarixin

    Dompe' Farmaceutici S.p.A.

    Recent onset Type 1 Diabetes

    phase 2 small molecule active

    1 trial

  9. Laminectomy

    Biotech Pharmaceutical Co.,

    Acute Spinal Cord Injury

    phase 2 other active

    1 trial

  10. Lapaquistat acetate and fenofibrate

    Takeda

    Hyperlipidemias

    phase 2 small molecule completed

    1 trial

  11. Larazotide Acetate

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  12. Lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Bone Loss

    phase 2 small molecule completed

    1 trial

  13. Leflunomide CF 20 mg, filmomhulde tabletten, Hydorxychloroquine 200mg/Placebo, Hydroxychloroquinesulfaat 200 mg Focus, filmomhulde tabletten, Hydroxychloroquinesulfaat CF 200 mg, filmomhulde tabletten, Leflunomide Mylan 10 mg, filmomhulde tabletten, Leflunomide 20mg/Placebo, Leflunomide Mylan 20 mg, filmomhulde tabletten, Plaquenil 200 mg, filmomhulde tabletten

    Disc Medicine

    primary Sjögren's Syndrome

    phase 2 small molecule active

    1 trial

  14. Lenabasum 20 mg

    Corbus Pharmaceuticals Holdings

    Cystic Fibrosis

    phase 2 small molecule completed

    1 trial

  15. Leuprolide acetate

    Voyager Therapeutics

    Alzheimer Disease

    phase 2 small molecule completed

    2 trials

  16. Linaclotide 145 micrograms

    IRONWOOD PHARMACEUTICALS INC

    Opioid-Induced Constipation

    phase 2 small molecule completed

    1 trial

  17. Linaclotide Acetate

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule completed

    1 trial

  18. Linaclotide Dose A

    IRONWOOD PHARMACEUTICALS INC

    Irritable Bowel Syndrome With Constipation

    phase 2 small molecule terminated

    1 trial

  19. Lintuzumab-Ac225

    Actinium Pharmaceuticals

    Acute Myeloid Leukemia

    phase 2 mab active

    2 trials

  20. Linvoseltamab, Diphenhydramine Hydrochloride 25 mg Tablets, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone 4 mg tablets, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Paracetamol 500 mg Film-Coated Tablets

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  21. Linvoseltamab, Linvoseltamab, RoActemra 20 mg/mL concentrate for solution for infusion, Dexamethasone phosphate 4 mg/ml solution for injection/infusion, Diphenhydramine Hydrochloride 25 mg Tablets, Paracetamol 500mg Tablets, REGN88, Dexamethasone 2mg Tablets

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  22. Lipid Lowering Medication

    Grace Therapeutics

    Hypertriglyceridemia

    phase 2 small molecule completed

    1 trial

  23. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

    phase 2 small molecule active

    1 trial

  24. Liposome-encapsulated Daunorubicin-Cytarabine

    Jazz Pharmaceuticals Ireland Limited

    Acute Myeloid Leukemia

    phase 2 small molecule active

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources